REG - Avacta Group PLC - AVA6000 Abstract Release by AACR

AvactaAnnouncement

08/04/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240408:nRSH5899Ja&default-theme=true

RNS Number : 5899J  Avacta Group PLC  08 April 2024

 

 

 
 
 
                     8 April 2024

 

Avacta Group plc

("Avacta" or "the Group" or "the Company")

 

AVA6000 Abstract Release by AACR and Full Presentation Update

 

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative,
targeted oncology drugs and powerful diagnostics, today announces that the
abstract of the poster to be presented at the American Association of Cancer
Research ("AACR") Annual Meeting in San Diego, California on Tuesday 9 April
has now been released by AACR.

 

The poster presentation will be based on data from the Phase 1a trial of
AVA6000, a peptide drug conjugate consisting of doxorubicin conjugated with a
peptide moiety that is specifically cleaved by fibroblast activation protein
(FAP) in the tumor microenvironment.

 

Christina Coughlin, MD, PhD, Head of Research & Development and Simon
Bennett, DPhil, Chief Business Officer, will be attending the conference with
colleagues.

 

 

Presentation details

Title: A Phase 1 trial of AVA6000, a Fibroblast Activation Protein
(FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide
drug conjugate in patients with FAP-positive solid tumors

Session Title: First-in-Human Phase 1 Clinical Trials 2

Session Date and Time: Tuesday 9 April 2024 9:00 AM - 12:30 PM (PDT)

Location: San Diego Convention Center, San Diego CA USA

Abstract Presentation Number: CT188

First Author: Udai Banerji, MD, PhD, The Institute of Cancer Research, London,
and The Royal Marsden NHS Foundation Trust

 

The presentation will include updated data from the Phase 1 trial beyond those
included in the abstract. A copy of the abstract will be available on Avacta's
website at: https://avacta.com/about/scientific-resources/
(https://avacta.com/about/scientific-resources/) .

 

Copies of the poster will be available on Avacta's website following the
conference at: https://avacta.com/about/resources/posters/
(https://avacta.com/about/resources/posters/) .

 

Christina Coughlin will provide a video presentation overview examining the
data presented in the poster. This will be available on 10th April at
https://avacta.com/investors/documents-presentations/
(https://avacta.com/investors/documents-presentations/) .

 

Alastair Smith, Avacta Chief Executive Officer, will also be hosting a webinar
on Wednesday, April 10 2024 at 5.30pm BST to discuss the data. Registration
for the event is via the following link:

https://www.turnerpope.com/register/
(https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.turnerpope.com%2Fregister%2F&data=05%7C02%7CAndy.Thacker%40TurnerPope.com%7C8296e62546d8483c282208dc4f330598%7Cff82bd738fe84a38a86994e58a240e55%7C0%7C0%7C638472331397061435%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&sdata=i335GQQaZEauqaF00Tbs6%2F1a9qu7mfSDE%2Fk8r0D8tFc%3D&reserved=0)

 

-Ends-

 

 

For further information from Avacta Group plc, please contact:

 

 Avacta Group plc                                                           Tel: +44 (0) 1904 21 7070

 Alastair Smith, Chief Executive Officer                                    www.avacta.com (http://www.avacta.com)

 Tony Gardiner, Chief Financial Officer

 Michael Vinegrad, Group Communications Director

 Stifel Nicolaus Europe Limited (Nomad and Joint Broker)                    Tel: +44 (0) 207 710 7600

 Nicholas Moore / Nick Adams / Samira Essebiyea / Nick Harland / Ben Good   www.stifel.com (http://www.stifel.com/)

                                                                            Tel: +44 (0) 207 418 8900

 Peel Hunt (Joint Broker)                                                   www.peelhunt.com (http://www.peelhunt.com)

 James Steel / Chris Golden / Patrick Birkholm

 ICR Consilium (Media and IR)                                               avacta@consilium-comms.com (mailto:avacta@consilium-comms.com)

 Mary-Jane Elliott / Jessica Hodgson / Sukaina Virji

 

 

 

About AVA6000

AVA6000, Avacta Therapeutics' lead oncology program, is a peptide drug
conjugate consisting of doxorubicin conjugated with a peptide moiety that is
specifically cleaved by fibroblast activation protein (FAP) in the tumor
microenvironment (TME). FAP is selectively overexpressed in many solid tumors.
The peptide moiety (pre|CISION(TM)) prevents cellular entry of doxorubicin
unless cleaved by FAP, thus enabling targeted delivery of doxorubicin directly
to the TME.

 

About Avacta Group plc - https://www.avacta.com (https://www.avacta.com/)

Avacta Group is a UK-based company focused on improving healthcare outcomes
through targeted cancer treatments and diagnostics.

 

Avacta has two divisions: an oncology biotech division harnessing proprietary
therapeutic platforms to develop novel, highly targeted cancer drugs, and a
diagnostics division, which is executing on an M&A led growth strategy to
create a full-spectrum diagnostics business focused on supporting healthcare
professionals and broadening access to testing. Avacta's two proprietary
platforms, Affimer® and pre|CISION™ underpin its cancer therapeutics whilst
the diagnostics division leverages the Affimer® platform to drive competitive
advantage in its markets.

 

The pre|CISION™ platform modifies chemotherapy to be activated only in the
tumour tissue, reducing systemic exposure and toxicity. This is achieved by
harnessing an enzyme called FAP which is highly upregulated in most solid
tumours compared with healthy tissues, turning chemotherapy into a "precision
medicine". The lead pre|CISION™ programme, AVA6000 a tumour activated form
of doxorubicin, is in Phase 1 studies and has shown dramatic improvement in
safety compared with standard doxorubicin, and early signs of clinical
activity.

 

 

To register for news alerts by email go to
https://avacta.com/investors/investor-news-email-alerts/
(https://avacta.com/investors/investor-news-email-alerts/)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCUPUQACUPCGBM